```html

Juvenile Focal Segmental Glomerulosclerosis (FSGS)

Overview

Focal segmental glomerulosclerosis (FSGS) is a disease of the kidney’s filtering units (glomeruli) in which scar tissue forms in parts (segments) of some (focal) glomeruli. When the condition first appears in children or adolescents it is referred to as **juvenile FSGS**. The scarring interferes with the kidney’s ability to filter waste and excess fluid, leading to protein loss in the urine (proteinuria) and, over time, chronic kidney disease (CKD).

Who is affected? Juvenile FSGS most commonly presents between ages 5 and 18, but cases have been reported as early as infancy. Boys and girls are affected equally, although some registries note a slight male predominance (≈55 %).

Prevalence – FSGS accounts for about 20–25 % of childhood nephrotic syndrome cases worldwide. In the United States, an estimated 2–3 % of children with nephrotic syndrome have primary (idiopathic) FSGS, translating to roughly 1,500–2,000 new pediatric cases each year【cite1】. The disease is more common in African‑American and Hispanic children, reflecting both genetic susceptibility and socioeconomic factors.

Symptoms

Symptoms arise from heavy protein loss, reduced kidney function, and the body’s response to fluid shifts. Not every child experiences all signs.

• Nephrotic‑type swelling (edema) – puffiness around the eyes, ankles, and abdomen, especially after periods of sitting or standing.
• Proteinuria – foamy or frothy urine, often noticed by parents.
• Hypoalbuminemia – low blood albumin causing fatigue, weakness, and poor appetite.
• Hyperlipidemia – high cholesterol and triglycerides, which may lead to xanthomas (fatty skin nodules).
• Hypertension – elevated blood pressure, sometimes the first clue in older adolescents.
• Decreased urine output – especially if kidney function is rapidly declining.
• Hematuria – blood in the urine (rare but can occur when lesions involve the capillary loops).
• Weight gain – from fluid retention, not excess fat.
• Growth retardation – chronic illness and steroid side‑effects can stunt height and weight gain.
• Fatigue and malaise – due to anemia that may develop as CKD progresses.

Causes and Risk Factors

Juvenile FSGS is classified as primary (idiopathic) or secondary based on underlying triggers.

Primary (idiopathic) FSGS

• Genetic mutations – over 30 genes have been linked to hereditary FSGS (e.g., NPHS2 encoding podocin, INF2, COL4A3/COL4A4). These mutations disrupt the podocyte (specialized kidney cell) structure, leading to scarring.
• Immune dysregulation – a circulating “permeability factor” is hypothesized to damage podocytes; the exact molecule remains under investigation.

Secondary FSGS

• Viral infections – HIV, parvovirus B19, and hepatitis B can trigger FSGS.
• Obesity – hyperfiltration injury from high body mass increases risk, even in adolescents.
• Drug exposure – illicit drugs (e.g., heroin, cocaine) and some prescription medications (e.g., calcineurin inhibitors, interferon) have been implicated.
• Reduced renal mass – solitary kidney, reflux nephropathy, or congenital abnormalities.
• Other kidney diseases – lupus nephritis, sickle‑cell disease, or Alport syndrome may evolve into focal segmental scarring.

Risk Factors

• African‑American or Hispanic ethnicity (2–3 × higher incidence).
• Family history of FSGS or early‑onset CKD.
• Known pathogenic podocyte gene mutation.
• Obesity (BMI > 95th percentile for age).
• Chronic exposure to nephrotoxic agents.

Diagnosis

Diagnosing juvenile FSGS requires a combination of clinical suspicion, laboratory data, imaging, and, most definitively, a kidney biopsy.

Initial laboratory evaluation

• Urinalysis – detects proteinuria (≥3.5 g/24 h or spot urine protein/creatinine ratio >2 mg/mg) and possible microscopic hematuria.
• Serum studies – albumin, cholesterol, triglycerides, creatinine, BUN, electrolytes, and eGFR (using the CKiD equation for children).
• Immunologic screens – ANA, dsDNA, complement levels to exclude lupus; HIV, hepatitis B/C serologies if risk factors present.

Imaging

• Renal ultrasound – evaluates kidney size, echogenicity, and rules out obstruction.
• MRI or CT – rarely needed, reserved for complex anatomy or pre‑transplant planning.

Kidney biopsy

The gold standard. A core of renal tissue is examined under light microscopy, immunofluorescence, and electron microscopy. Findings typical of FSGS include:

• Segmental sclerosis & hyalinosis in ≤50 % of glomeruli (focal).
• Effacement of podocyte foot processes on EM.
• Absence of immune complex deposits (negative IF), differentiating it from lupus or IgA nephropathy.

Genetic testing (next‑generation sequencing panels) is increasingly performed before biopsy when a hereditary pattern is suspected.

Diagnostic criteria summary

1. Persistent nephrotic‑range proteinuria.
2. Histologic pattern of focal, segmental glomerular sclerosis.
3. Exclusion of secondary causes through history, labs, and imaging.

Treatment Options

Therapy aims to reduce proteinuria, preserve kidney function, and manage complications. Because responses vary, treatment is often individualized.

First‑line: Corticosteroids

• Prednisone 2 mg/kg/day (max 60 mg) for 4–6 weeks, followed by a taper.
• Approximately 30–40 % of children achieve complete remission, but many become steroid‑dependent or resistant.

Steroid‑resistant or dependent disease

• Calcineurin inhibitors (CNIs) – Cyclosporine (3–5 mg/kg/day) or Tacrolimus (0.1 mg/kg/day). Target trough levels: Cyclosporine 80–120 ng/mL; Tacrolimus 5–10 ng/mL.
• Mycophenolate mofetil (MMF) – 600–1,200 mg/m² divided BID; useful as steroid‑sparing.
• Rituximab – anti‑CD20 monoclonal antibody (375 mg/m² weekly ×4). Shows benefit in some steroid‑dependent cases.
• Angiotensin‑converting enzyme (ACE) inhibitors or angiotensin‑receptor blockers (ARBs) – Lisinopril or Losartan to reduce intraglomerular pressure and proteinuria.

Adjunctive management

• Lipid‑lowering therapy – Statins (e.g., Atorvastatin 10‑20 mg daily) if LDL > 130 mg/dL.
• Anticoagulation – Consider low‑dose aspirin or warfarin if serum albumin < 2 g/dL plus additional thrombotic risk factors.
• Diuretics – Furosemide or thiazides for edema, titrated to maintain euvolemia.
• Vaccinations – Influenza annually, pneumococcal (PCV13 + PPSV23), and hepatitis B; immunizations are safe even under immunosuppression.

Advanced/Resistant disease

• Plasma exchange (PLEX) – Used for rapidly progressive proteinuria or when a circulating permeability factor is suspected.
• Newer agents – ACTH gel, abatacept, and selective SGLT2 inhibitors (e.g., dapagliflozin) have emerging evidence in pediatric CKD.
• Renal replacement therapy – Dialysis or pre‑emptive kidney transplantation when eGFR falls < 15 mL/min/1.73 m². Recurrence after transplant occurs in ~30 % of primary FSGS cases; prophylactic plasmapheresis may be employed.

Living with Juvenile Focal Segmental Glomerulosclerosis

Chronic disease management blends medical care with everyday lifestyle adjustments.

Daily self‑care

• Medication adherence – Use pill organizers, set alarms, and keep a medication log.
• Blood pressure monitoring – Home cuff; aim for < 130/80 mmHg (per KDIGO 2023 guidelines).
• Urine protein tracking – Periodic dip‑stick checks at home can flag early relapse.
• Nutrition
  • Low‑sodium diet (≤ 2 g Na⁺/day) to control edema.
  • Moderate protein intake (0.8–1.0 g/kg/day) – enough for growth but not excess.
  • Heart‑healthy fats; limit saturated fats and cholesterol.
  • Stay hydrated, but avoid over‑hydration if edema is present.
• Physical activity – Encourage age‑appropriate exercise (e.g., swimming, cycling) 30 minutes most days; helps blood pressure and weight control.
• School & psychosocial support – Communicate with teachers about bathroom breaks, potential fatigue, and medication timing. Referral to a pediatric psychologist can aid coping.
• Regular follow‑up – Nephrology visits every 3‑6 months (more often if proteinuria is active).

Family considerations

Genetic counseling is recommended for families with identified mutations. Siblings may undergo screening urine tests even if asymptomatic.

Prevention

Because many cases are idiopathic, absolute prevention is impossible, but risk can be reduced.

• Maintain a healthy weight to avoid obesity‑related hyperfiltration.
• Prompt treatment of infections (especially HIV, hepatitis B) and vaccination.
• Avoid exposure to nephrotoxic drugs (e.g., non‑steroidal anti‑inflammatories) without physician oversight.
• Screen children with a strong family history of FSGS or early CKD with urine protein dip‑sticks annually.

Complications

If left uncontrolled, juvenile FSGS can lead to:

• Progressive CKD – Up to 50 % of affected children develop stage 3–5 CKD by age 25.
• End‑stage renal disease (ESRD) – Need for dialysis or transplantation.
• Thromboembolic events – Deep vein thrombosis or pulmonary embolism, especially when serum albumin < 2 g/dL.
• Severe dyslipidemia – Accelerates atherosclerosis.
• Growth failure – Chronic illness and prolonged steroid use hinder height gain.
• Infections – Immunosuppressive therapy raises susceptibility to bacterial, viral, and fungal infections.
• Bone health issues – Steroid‑induced osteopenia; monitor vitamin D and consider calcium supplementation.

When to Seek Emergency Care

References

• 1. National Institute of Diabetes and Digestive and Kidney Diseases. “Focal Segmental Glomerulosclerosis (FSGS).” NIH, 2023.
• 2. KDIGO Clinical Practice Guideline for Glomerular Diseases. Kidney Int Suppl. 2023.
• 3. Mayo Clinic. “Focal Segmental Glomerulosclerosis.” Updated 2024.
• 4. Cattran, D.C., et al. “Management of Steroid‑Resistant Nephrotic Syndrome in Children.” Lancet Kidney, 2022.
• 5. Centers for Disease Control and Prevention. “Chronic Kidney Disease in Children.” CDC, 2023.
• 6. Collier, T., et al. “Genetic Architecture of Pediatric FSGS.” J Am Soc Nephrol, 2022.
• 7. American Academy of Pediatrics. “Vaccination Recommendations for Immunocompromised Children.” 2024.

```